Citi Pharma Ltd

Citi Pharma maintains a conservative capital structure with a debt-to-equity ratio of 0.27, indicating a relatively low reliance on debt financing. The company's liquidity position is characterized as medium, with a current ratio of 1.3, suggesting it can cover short-term obligations but with limited buffer. Free cash flow of PKR 234.18 million indicates positive cash generation from operations after capital expenditures, though operating cash flow is negative at PKR -320.70 million, reflecting potential working capital constraints. Profitability metrics show a return on equity (ROE) of 8.21% and a return on assets (ROA) of 4.84%, both below the typical thresholds for high-performing pharmaceutical firms. Gross profit of PKR 2.02 billion and operating income of PKR 1.60 billion suggest moderate efficiency in cost management, but net income of PKR 892.04 million indicates a need for improvement in translating gross profit into net returns. The company's revenue is concentrated across three primary segments: API, formulations, and research and development. API products, including Paracetamol and Amoxicillin, form a significant portion of its offerings, while formulations include a range of dosage forms such as tablets and injectables. Geographic exposure is primarily within Pakistan, with no disclosed international revenue streams, which may limit diversification benefits. Growth trajectory appears modest, with no disclosed revenue growth rates or future projections. The company's capital expenditure of PKR -86.12 million suggests a focus on maintaining rather than expanding production capacity. Analyst estimates align with reported revenue and EPS, indicating stable but not accelerating performance. Risk factors include medium liquidity risk due to negative net cash after subtracting total debt, and low dilution risk as shares outstanding remain unchanged between basic and diluted measures. No recent dilutive events or capital-raising activities are disclosed, and the company has not issued new shares in the latest reporting period. Recent filings and transcripts do not disclose material events or strategic shifts. The company's operations remain focused on its core manufacturing and R&D activities, with no significant new product launches or market expansions reported in the latest financial period.